Raynaud's phenomenon in connective tissue diseases;Phenomene de Raynaud et connectivites

Revue du Praticien

Volumn 48, Issue 15, 1998, Pages 1647-1652

  Guilmot, Jean Louis ^a   Diot, Elisabeth ^a   Lasfargues, Gérard ^a   Boissier, Christian ^b  

^a CHU BRETONNEAU   (France)

^b HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSEL REACTIVITY; BUERGER DISEASE; CONNECTIVE TISSUE DISEASE; FRANCE; HUMAN; PATHOPHYSIOLOGY; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; LOCALIZED SCLERODERMA; PREVALENCE;

ANTIBODY;

ANTIBODIES; CONNECTIVE TISSUE DISEASES; HUMANS; PREVALENCE; RAYNAUD DISEASE; SCLERODERMA, LOCALIZED;

EID: 0032189525     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Maricq HR, Carpentier PH,Weinrich MC et al. Geographic variatíon in the prevalence of Raynaud's phenomenon :a 5 region comparison. J Rheumatol 1997 ; 24 : 879-89.
2. Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 1990 ; 301 : 590-2.
3. Grassi W, Blasetti P, Core P, Cervini C. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1994 ; 33 : 139-41.
4. Zufferey P, Depairon M, Chamot AM, Monti M. Prognostic signifiance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma pattern abnormalities. Clin Rheumatol 1992 ; 11 : 536-41.
5. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 1996 ; 15 : 148-53.
6. Hang LM, Nakamura RM. Current concepts and advances in clinical laboratory testing for autoimmune diseases. Crit Rev Clin Lab Sci 1997 ; 34 : 275-311.
7. Okano Y, Steen V, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Med Intern 1993 ; 119 : 1005-13.
8. Maricq HR, Weinrich MC, Valter I, Palesch YY, Maricq JG. Digital vascular response to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. J Rheumatol 1996 ; 23 : 2068-78.
9. Vayssairat M, Evenou P, Baudot N, Priollet P, Gilard M.A new cold test for the diagnosis of Raynaud's phenomenon. Ann Vasc Surg 1987 ; 1 : 474-8.
10. Dowd P, Goldsmith P, Burnstock G, Marshall I, Bull H, Foreman J. Raynaud's phenomenon. Lancet 1995 ; 346 : 283-90.
11. Wigley F,Wise R, Seibold J et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis :a multicenter, placebo controlled, double blind study. Ann Intern Med 1994 ; 120 : 199-206.
12. Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd M. Calcitonin-gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993 ; 342 : 80-3.
13. Caspary L, Schmees C, Schoetensac I, et al. Alterations of the nailfold capillary morphology associated with Raynaud phenomenon in patients with systemic lupus erythematosus. J Rheumatol 1991 ; 18 : 559-66.
14. Bongard O, Mischer PA, Bounameaux H. Altered skin microcirculation in patients with systemic lupus erythematosus. Int J Microcirc Clin Exp 1997 ; 17 : 184-9.
15. Vayssairat M, Baudot N, Gaitz JP. Raynaud's phenomenon together with antinuclear antibodies : a common subset of incomplete connective tissue disease. J Am Acad Dermatol 1995 ; 32 : 747-9.
16. Gulati S, Madhra K, Thusoo TK, Nair SK, Saha K. Autoantibodies in thromboangiitis obliterans. Angiology 1982 ; 33 : 642-51.